Back to top

Analyst Blog

GlaxoSmithKline (GSK - Analyst Report) and Theravance, Inc. (THRX - Analyst Report) recently announced data from four pivotal phase III studies conducted with their pipeline candidate, LAMA/LABA (UMEC/VI), for chronic obstructive pulmonary disease (COPD). LAMA/LABA is a combination of a long-acting muscarinic antagonist/LAMA (GSK573719 or umeclidinium bromide/UMEC) and a long-acting beta2 agonist/LABA (vilanterol/VI).

While two studies compared the efficacy and safety of LAMA/LABA with VI, UMEC and placebo, the other two other studies compared the efficacy and safety of LAMA/LABA with Pfizer’s (PFE - Analyst Report) Spiriva. Spiriva is commonly used as a maintenance treatment for COPD. The four studies together enrolled over 4,000 COPD patients.

In both the placebo-controlled, 24-week, randomized, double-blind studies, LAMA/LABA showed a statistically significant benefit over VI, UMEC and placebo. In the first head-to-head comparison with Spiriva, LAMA/LABA showed a statistically significant improvement. However, in the second study, LAMA/LABA failed to do so although it demonstrated numerical difference.

Currently, a 52-week safety study and two replicate 12-week crossover exercise studies are ongoing for LAMA/LABA. Glaxo plans to submit regulatory applications for LAMA/LABA towards the end of 2012.  

Our Take

LAMA/LABA, if approved, will be positioned as a replacement for Advair, one of Glaxo’s highest revenue earners with 2011 sales exceeding £5 billion. We note that Glaxo along with Theravance is also developing other COPD candidates including Relovair and MABA (GSK961081).

Earlier in May 2012, Glaxo had acquired 10,000,000 shares of Theravance for approximately $21.2887 per share. With this transaction, Glaxo increased its holding in Theravance to 26.7% from 18.3%. The increased holding by Glaxo reflects its confidence in the pipeline candidates.

We currently have Neutral recommendations on both Glaxo and Theravance. Both the stocks carry a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 2.99 +2.75%
CTPARTNERS… CTP 16.25 +2.33%
CHINA BIOLO… CBPO 46.93 +1.88%
THE PANTRY… PTRY 20.93 +1.65%
NN INC NNBR 28.43 +1.46%